Factor V New Brunswick: Ala221Val associated with FV deficiency reproduced in vitro and functionally characterized

Blood

Volumn 102, Issue 4, 2003, Pages 1316-1322

  Steen, Mårten ^b   Miteva, Maria ^b   Villoutreix, Bruno O ^b   Yamazaki, Tomio ^b   Dahlbäck, Björn ^a  

^a LUND UNIVERSITY   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ALANYLVALINE; AMINO ACID; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR V NEW BRUNSWICK; CYSTEINYLALANINE; GLUTAMYLGLUTAMINE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING FACTOR 5 DEFICIENCY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISSOCIATION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; EXPERIMENT; FUNCTIONAL ASSESSMENT; HUMAN; IN VITRO STUDY; MISSENSE MUTATION; MOLECULAR BIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN SECRETION; PROTEIN STABILITY; PROTEIN SYNTHESIS; TEMPERATURE;

EID: 0042738950     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-01-0116     Document Type: Article

References (37)

1. Kane WH, Davie EW. Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood. 1988;71:539-555.
2. Nesheim ME, Mann KG. Thrombin-catalyzed activation of single chain bovine factor V. J Biol Chem. 1979;254:1326-1334.
3. Esmon CT. The subunit structure of thrombin-activated factor V. Isolation of activated factor V, separation of subunits, and reconstitution of biological activity. J Biol Chem. 1979;254:964-973.
4. Suzuki K, Dahlback B, Stenflo J. Thrombin-catalyzed activation of human coagulation factor V. J Biol Chem. 1982;257:6556-6564.
5. Monkovic DD, Tracy PB. Activation of human factor V by factor Xa and thrombin. Biochemistry. 1990;29:1118-1128.
6. Thorelli E, Kaufman RJ, Dahlback B. Cleavage requirements for activation of factor V by factor Xa. Eur J Biochem. 1997;247:12-20.
7. Nesheim ME, Taswell JB, Mann KG. The contribution of bovine factor V and factor Va to the activity of prothrombinase. J Biol Chem. 1979;254: 10952-10962.
8. Rosing J, Tans G, Govers-Riemslag JW, Zwaal RF, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem. 1980;255:274-283.
9. Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood. 1990;76:1-16.
10. Owren P. Parahemophilia: hamorrhagic diathesis due to absence of a previously unknown clotting factor. Lancet. 1947;1:446-448.
11. van Wijk R, Nieuwenhuis K, van den Berg M, et al. Five novel mutations in the gene for human blood coagulation factor V associated with type I factor V deficiency. Blood. 2001;98:358-367.
12. Peyvandi F, Mannucci PM. Rare coagulation disorders. Thromb Haemost. 1999;82:1207-1214.
13. Kemball-Cook G, Tuddenham EG. The Factor VIII Mutation Database on the World Wide Web: the haemophilia A mutation, search, test and resource site. HAMSTeRS update (version 3.0). Nucleic Acids Res. 1997;25:128-132.
14. Ajzner EE, Balogh I, Szabo T, Marosi A, Haramura G, Muszbek L. Severe coagulation factor V deficiency caused by 2 novel frameshift mutations: 2952delT in exon 13 and 5493insG in exon 16 of factor 5 gene. Blood. 2002;99:702-705.
15. Bossone A, D'Angelo F, Santacroce R, De Lucia D, Margaglione M. Factor V Arg2074Cys: a novel missense mutation in the C2 domain of factor V. Thromb Haemost. 2002;87:923-924.
16. Murray JM, Rand MD, Egan JO, Murphy S, Kim HC, Mann KG. Factor VNew Brunswick: Ala221-to-Val substitution results in reduced cofactor activity. Blood. 2002;86:1820-1827.
17. Steen M, Villoutreix BO, Norstrom EA, Yamazaki T, Dahlback B. Defining the factor Xa-binding site on factor Va by site-directed glycosylation. J Biol Chem. 2002;277:50022-50029.
18. Kaufman RJ. Vectors used for expression in mammalian cells. Methods Enzymol. 1990;185: 487-511.
19. Shen L, Shah AM, Dahlback B, Nelsestuen GL. Enhancing the activity of protein C by mutagenesis to improve the membrane-binding site: studies related to proline-10. Biochemistry. 1997;36: 16025-16031.
20. Steen M, Dahlback B. Thrombin-mediated proteolysis of factor V resulting in gradual B-domain release and exposure of the factor Xa-binding site. J Biol Chem. 2002;277:38424-38430.
21. Katsumi A, Senda T, Yamashita Y, et al. Protein C Nagoya, an elongated mutant of protein C, is retained within the endoplasmic reticulum and is associated with GRP78 and GRP94. Blood. 1996;87:4164-4175.
22. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
23. Thorelli E, Kaufman RJ, Dahlback B. Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V. Blood. 1999;93:2552-2558.
24. Norstrom E, Thorelli E, Dahlback B. Functional characterization of recombinant FV Hong Kong and FV Cambridge. Blood. 2002;100:524-530.
25. Thorelli E, Kaufman RJ, Dahlback B. Cleavage requirements of factor V in tissue-factor induced thrombin generation. Thromb Haemost. 1998;80: 92-98.
26. Nesheim ME, Katzmann JA, Tracy PB, Mann KG. Factor V. Methods Enzymol. 1981;80:249-274.
27. Villoutreix BO, Dahlback B. Structural investigation of the A domains of human blood coagulation factor V by molecular modeling. Protein Sci. 1998;7:1317-1325.
28. Duga S, Montefusco MC, Asselta R, et al. R2074C missense mutation in the C2-domain of factor V causing moderately severe factor V deficiency: molecular characterization by expression of the recombinant protein. Blood. 2003;1:173-177.
29. Ortel TL, Devore-Carter D, Quinn-Allen M, Kane WH. Deletion analysis of recombinant human factor V. Evidence for a phosphatidylserine binding site in the second C-type domain. J Biol Chem. 1992;267:4189-4198.
30. Bakker HM, Tans G, Thomassen MC, et al. Functional properties of human factor Va lacking the Asp683-Arg709 domain of the heavy chain. J Biol Chem. 1994;269:20662-20667.
31. Camire RM, Kalafatis M, Tracy PB. Proteolysis of factor V by cathepsin G and elastase indicates that cleavage at Arg1545 optimizes cofactor function by facilitating factor Xa binding. Biochemistry. 1998;37:11896-11906.
32. Nicolaes GA, Tans G, Thomassen MC, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem. 1995;270:21158-21166.
33. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem. 1994;269:31869-31880.
34. Pemberton S, Lindley P, Zaitsev V, Card G, Tuddenham EG, Kemball-Cook G. A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood. 1997;89:2413-2421.
35. Heeb MJ, Kojima Y, Hackeng TM, Griffin JH. Binding sites for blood coagulation factor Xa and protein S involving residues 493-506 in factor Va. Protein Sci. 1996;5:1883-1889.
36. Kojima Y, Heeb MJ, Gale AJ, Hackeng TM, Griffin JH. Binding site for blood coagulation factor Xa involving residues 311-325 in factor Va. J Biol Chem. 1998;273:14900-14905.
37. Kalafatis M, Beck DO. Identification of a binding site for blood coagulation factor Xa on the heavy chain of factor Va. Amino acid residues 323-331 of factor V represent an interactive site for activated factor X. Biochemistry. 2002;41:12715-12728.